- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr. Jeff Goldsmith Addresses the Unintended Consequences of ACOs
Jeff Goldsmith, PhD, President, Health Futures, Inc, Associate Professor of Public Health Sciences, University of Virginia, says that the biggest barrier that accountable care organizations (ACOs) face is the lack of collaboration between physician communities and hospitals.
Jeff Goldsmith, PhD, President, Health Futures, Inc, Associate Professor of Public Health Sciences, University of Virginia, says that the biggest barrier that accountable care organizations (ACOs) face is the lack of collaboration between physician communities and hospitals. "You are trying to create a managed care environment without a lot of the tools or values that promote effective managed care activity," said Dr Goldsmith.
Dr Goldsmith thinks that The ACO is viewed as a collective effort with no competition in its model. Patients will not have the choice to either be in an ACO or not, and there will be no financial incentives to choose an ACO. "So, I don't think the issue of choice played that much of a role, and if you don't have choice you don't have competition."
This video was taken at AHIP's ACO Summit in Washington, DC on May 15, 2013.
A meta-analysis showed that control group outcomes in psilocybin trials for depression were significantly weaker than those in selective serotonin reuptake inhibitor (SSRI) and esketamine trials, suggesting that psilocybin’s large observed treatment effects may be inflated by methodological factors such as functional unblinding and expectancy bias.
Read More
Linvoseltamab Added as Preferred Agent in Newest MM Practice Guidelines
July 31st 2025On July 2, linvoseltamab-gcpt (Lynozyfic; Regeneron) received an accelerated approval from the FDA in relapsed/refractory multiple myeloma (MM), and the most recent update to the National Comprehensive Cancer Network guidelines for MM has added the BCMA-targeted bispecific antibody as a preferred treatment option.
Read More
